{"entity":{"id":"plb-004","kind":"drug","name":"PLB-004","aka":[],"tldr":"PLB-004 is an experimental antibody-drug conjugate from PrimeLink BioTherapeutics, in preclinical development for solid tumours.","summary":"PLB-004 is an antibody-drug conjugate from PrimeLink BioTherapeutics. Antibody-drug conjugate in PrimeLink's pipeline; the target is not disclosed in the sources read. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Listed on the pipeline page (columns: discovery, preclinical, IND, phase I); the stage bar is graphical and was not read; no registry entry found for this code via the v2 API. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"PrimeLink BioTherapeutics: primelinkbio.com","url":"https://www.primelinkbio.com/pipeline/1.html"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["primelink-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PLB-004","modality":"Antibody-drug conjugate","mechanism":"Antibody-drug conjugate in PrimeLink's pipeline; the target is not disclosed in the sources read.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/plb-004/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"primelink-biotherapeutics","kind":"company","name":"PrimeLink BioTherapeutics","route":"/companies/primelink-biotherapeutics/"}]}}